{"id":2217,"date":"2025-11-03T11:15:08","date_gmt":"2025-11-03T10:15:08","guid":{"rendered":"https:\/\/dextechmedical.com\/?p=2217"},"modified":"2025-11-03T10:47:36","modified_gmt":"2025-11-03T09:47:36","slug":"interim-report-july-1-september-30-2025","status":"publish","type":"post","link":"https:\/\/dextechmedical.com\/en\/interim-report-july-1-september-30-2025\/","title":{"rendered":"Interim report July 1- September 30, 2025"},"content":{"rendered":"<p><strong>Summary of the first quarter (2025-07-01 \u2013 2025-09-30)<\/strong><\/p>\n<ul>\n<li>Net sales amounted to MSEK 0.0 (0.0)<\/li>\n<li>Operating profit\/loss amounted to MSEK -1.3 (-1.3)<\/li>\n<li>Earnings per share* SEK -0.07 (-0.06)<\/li>\n<li>Cash and cash equivalents at the end of the interim period amounted to MSEK 14.1 (14.7).<\/li>\n<\/ul>\n<p><em>* Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 18,485,857. Amounts in brackets refer to the corresponding period last year.<\/em><\/p>\n<p><strong>Comments from the CEO<\/strong><\/p>\n<p>The ongoing myeloma study is being conducted at Uddevalla Hospital, PI (principal investigator) Dr Dorota Knut and at Karolinska University Hospital, Huddinge, PI Dr Katarina Uttervall dept. Hematol-ogy\/HERM. Biomarkers are analysed at the Central Laboratory, Karolinska University Hospital, NKS, Solna.<br \/>\nThe primary objective is to confirm safety and tolerability and as a secondary objective to determine indications of treatment response. The patients who can be included in the study (inclusion criteria), must have relapsed\/treatment-resistant disease and received 1-5 prior lines of therapy.<br \/>\nTreatment with ODX is given in a maximum of 7 doses, one dose every two weeks. Patients are di-vided into 3 dose groups, 3mg\/kg, 6mg\/kg and 9mg\/kg, 4 patients in each group.<br \/>\nAn addition to the study protocol enables follow-up of patients who responded to ODX treatment and refers to the time to new disease progression after completion of ODX treatment. No other anti-cancer treatment is given during the follow-up period.<br \/>\nDose group 2 (6mg\/kg) has been fully recruited. Two of the patients had progressive disease after completion of treatment and the other 2 patients are expected to complete their treatment in early De-cember.<br \/>\nFollow-up of all patients who had so far achieved stable disease shows that the disease-inhibiting ef-fect lasted at most just over six months without initiation of other cancer treatment.<br \/>\nA meeting of the DMC (Independent Data Monitoring Committee) was held in early October and ap-proved the continuation to dose group 3. One patient for dose group 3 has been screened and re-ceived his first dose at the end of October.<br \/>\nThe results so far, i.e. for patients with relapsed\/treatment-resistant disease, must be seen as promis-ing with a majority achieving stable disease, and, without serious side effects.<br \/>\n<em>Anders R Holmberg<\/em><\/p>\n<p><a href=\"https:\/\/dextechmedical.com\/wp-content\/uploads\/DexTech-Interim-report-July-September-2025.pdf\">DexTech &#8211; Interim report July &#8211; September 2025<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Summary of the first quarter (2025-07-01 \u2013 2025-09-30) Net sales amounted to MSEK 0.0 (0.0) Operating profit\/loss amounted to MSEK -1.3 (-1.3) Earnings per share* SEK -0.07 (-0.06) Cash and [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-2217","post","type-post","status-publish","format-standard","hentry","category-okategoriserade-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Interim report July 1- September 30, 2025 | DexTech<\/title>\n<meta name=\"description\" content=\"Summary of the first quarter (2025-07-01 \u2013 2025-09-30) Net sales amounted to MSEK 0.0 (0.0) Operating profit\/loss amounted to MSEK -1.3 (-1.3) Earnings\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dextechmedical.com\/?p=2213\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Interim report July 1- September 30, 2025 | DexTech\" \/>\n<meta property=\"og:description\" content=\"Summary of the first quarter (2025-07-01 \u2013 2025-09-30) Net sales amounted to MSEK 0.0 (0.0) Operating profit\/loss amounted to MSEK -1.3 (-1.3) Earnings\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dextechmedical.com\/?p=2213\" \/>\n<meta property=\"og:site_name\" content=\"DexTech\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-03T10:15:08+00:00\" \/>\n<meta name=\"author\" content=\"G\u00f6sta Lundgren\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"G\u00f6sta Lundgren\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dextechmedical.com\/?p=2213\",\"url\":\"https:\/\/dextechmedical.com\/?p=2213\",\"name\":\"Interim report July 1- September 30, 2025 | DexTech\",\"isPartOf\":{\"@id\":\"https:\/\/dextechmedical.com\/#website\"},\"datePublished\":\"2025-11-03T10:15:08+00:00\",\"author\":{\"@id\":\"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c\"},\"description\":\"Summary of the first quarter (2025-07-01 \u2013 2025-09-30) Net sales amounted to MSEK 0.0 (0.0) Operating profit\/loss amounted to MSEK -1.3 (-1.3) Earnings\",\"breadcrumb\":{\"@id\":\"https:\/\/dextechmedical.com\/?p=2213#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dextechmedical.com\/?p=2213\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dextechmedical.com\/?p=2213#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/dextechmedical.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Interim report July 1- September 30, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dextechmedical.com\/#website\",\"url\":\"https:\/\/dextechmedical.com\/\",\"name\":\"DexTech\",\"description\":\"Ett svenskt forskningsf\u00f6retag specialiserat p\u00e5 urologisk onkologi fr\u00e4mst prostatacancer\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dextechmedical.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c\",\"name\":\"G\u00f6sta Lundgren\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dextechmedical.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g\",\"caption\":\"G\u00f6sta Lundgren\"},\"sameAs\":[\"https:\/\/dextechmedical.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Interim report July 1- September 30, 2025 | DexTech","description":"Summary of the first quarter (2025-07-01 \u2013 2025-09-30) Net sales amounted to MSEK 0.0 (0.0) Operating profit\/loss amounted to MSEK -1.3 (-1.3) Earnings","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dextechmedical.com\/?p=2213","og_locale":"en_US","og_type":"article","og_title":"Interim report July 1- September 30, 2025 | DexTech","og_description":"Summary of the first quarter (2025-07-01 \u2013 2025-09-30) Net sales amounted to MSEK 0.0 (0.0) Operating profit\/loss amounted to MSEK -1.3 (-1.3) Earnings","og_url":"https:\/\/dextechmedical.com\/?p=2213","og_site_name":"DexTech","article_published_time":"2025-11-03T10:15:08+00:00","author":"G\u00f6sta Lundgren","twitter_misc":{"Written by":"G\u00f6sta Lundgren","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/dextechmedical.com\/?p=2213","url":"https:\/\/dextechmedical.com\/?p=2213","name":"Interim report July 1- September 30, 2025 | DexTech","isPartOf":{"@id":"https:\/\/dextechmedical.com\/#website"},"datePublished":"2025-11-03T10:15:08+00:00","author":{"@id":"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c"},"description":"Summary of the first quarter (2025-07-01 \u2013 2025-09-30) Net sales amounted to MSEK 0.0 (0.0) Operating profit\/loss amounted to MSEK -1.3 (-1.3) Earnings","breadcrumb":{"@id":"https:\/\/dextechmedical.com\/?p=2213#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dextechmedical.com\/?p=2213"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/dextechmedical.com\/?p=2213#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/dextechmedical.com\/en\/"},{"@type":"ListItem","position":2,"name":"Interim report July 1- September 30, 2025"}]},{"@type":"WebSite","@id":"https:\/\/dextechmedical.com\/#website","url":"https:\/\/dextechmedical.com\/","name":"DexTech","description":"Ett svenskt forskningsf\u00f6retag specialiserat p\u00e5 urologisk onkologi fr\u00e4mst prostatacancer","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dextechmedical.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c","name":"G\u00f6sta Lundgren","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dextechmedical.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g","caption":"G\u00f6sta Lundgren"},"sameAs":["https:\/\/dextechmedical.com"]}]}},"_links":{"self":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts\/2217","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/comments?post=2217"}],"version-history":[{"count":1,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts\/2217\/revisions"}],"predecessor-version":[{"id":2220,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts\/2217\/revisions\/2220"}],"wp:attachment":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/media?parent=2217"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/categories?post=2217"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/tags?post=2217"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}